Clinical trials of ICIs in advanced MSI colorectal cancer
| Studies | NCT | Phase | N | Drug | BOR (%) | CR (%) | DFR (%)2-year | DFR (%)3-year | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Lenz, 2022 | NCT04008030 | II/1L | 45 | Ipilimumab/nivolumab | 65 | 13 | 73 (57–84.5) | - | [32] |
| André, 2022 | NCT02060188 | II/≥ 2L | 119 | Ipilimumab/nivolumab | 55 | 3 | 63 (53–71) | 60 (50–68) | [35] |
| Overman, 2018 | NCT02060188 | II/≥ 2L | 74 | Nivolumab | 51 | 3 | 50 (38–61) | - | [34] |
| Overman, 2024 | NCT02060188 | II/> 2L | 50 | Relatlimab/nivolumab | 48 | 16 | 51 (37–64) | 38 (24–52) | [36] |
| Le, 2020 | NCT02460198 | II/2L | 61 | Pembrolizumab | 33 | 3 | 31 | - | [40] |
| Le, 2020 | NCT02460198 | II/> 2L | 63 | Pembrolizumab | 33 | 8 | 37 | - | [40] |
| Diaz, 2022 | NCT02563002 | III/1L | 307 | Pembrolizumab vs CHT | 45 vs 33 | 13 vs 4 | 48.3 (39.9–56.2) | 42.3 (34–50.4) vs 11.1 (6.1–17.9) | [42] |
| Andre, 2024 | NCT04008030 | III/1L | 505 | Ipilimumab/nivolumab vs nivolumab vs CHT | - | - | 72 vs 14 | - | [43] |
| Kim, 2020 | NCT03150706 | II/> 2L | 30 | Avelumab | 24 | 14 | - | - | [37] |
| Taïeb, 2023 | NCT03186326 | II/2L | 122 | Avelumab vs CHT | 30 vs 26 | 7 vs 5 | 25 vs 10 | - | [38] |
| Oh, 2022 | NCT03435107 | II/> 2L | 30 | Durvalumab | 42 | - | - | - | [39] |
ICIs: immune checkpoint inhibitors; MSI: microsatellite unstable; ipilimumab: anti-CTLA4; nivolumab: anti-PD-1; relatimab: anti-LAG3; pembrolizumab: anti-PD-1; CHT: chemotherapy; avelumab: anti-PD-L1; durvalumab: anti-PD-L1; BOR: best overall response; CR: complete response; DFR: disease-free rate; NCT: National Clinical Trial; Ref.: reference